Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 19/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 15/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.35 |
| ▸ | USP14 | P54578 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4083199 | 0.86 | S1PR1 (0.38) | S1PR5S1PR1 | |
| SCHEMBL19306519 | 0.75 | KLK7 (0.41) | — | |
| SCHEMBL11079024 | 0.72 | TSHR (0.49) | — | |
| SCHEMBL4095084 | 0.72 | BACE1 (0.35) | S1PR5S1PR1S1PR4USP14 | |
| SCHEMBL5029906 | 0.70 | CA2 (0.48) | — | |
| SCHEMBL3722014 | 0.70 | RXRA (0.51) | — | |
| SCHEMBL17361958 | 0.70 | APP (0.44) | — | |
| SCHEMBL12639204 | 0.69 | CYP17A1 (0.55) | — | |
| SCHEMBL6037914 | 0.69 | MAPT (0.40) | — | |
| SCHEMBL1313112 | 0.68 | LOXL2 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | S1PR5 2429/4885S1PR1 1120/4885S1PR4 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.